Research paper requirements:

Topic:
Induced pluripotent Stem Cell Therapy for Neurodegenerative Diseases

Objectives;
To write a review paper the on the recent development (past 5-7 years) in the field of Induced pluripotent Stem Cell such as different method of reprogramming the cell and the breakthroughs . Further, the paper will discuss the current research and studies on IPCS therapy for different Neurodegenrative diseases such as ALS, Alzheimer and Parkinson. the paper will conclude with the comparison of this studies and evaluates if any of this therapeutic efforts look promising.

Final Requirements:
• Complete a 20 page research paper in 12 pt. font, 1” margins, double-spaced
• Work cited page which includes a minimum of 15 peer-reviewed scientific papers
• (WRITER: 10 references has picked in the last 2 page of this document that must be used, you can pick the rest yourself )

FORMAT FOR THE PAPER
Scientific research articles provide a method for scientists to communicate with other scientists about the results of their research. A standard format is used for these articles, in which the author presents the research in an orderly, logical manner. This doesn’t necessarily reflect the order in which you did or thought about the work. This format is:
I. Introduction
A. Background
B. Hypothesis
C. Objectives
II. Methods
III. Discussion
A. Data for each objective
B. Accept or reject your hypothesis

FIGURES, TABLES AND GRAPHS
1. If you present data in a figure, the figure must have a figure legend below
2. If you present data in a table, the table must have a title above
REFERENCES (LITERATURE CITED)
references are to be in the same format as the ACS Journal Biochemistry. See authors’ instructions for more details and examples:
https://pubs.acs.org/page/bichaw/submission/reference-guidelines.html

DEAR WRITER; PLEASE USE all this references, in addition to any other ones that you would like. (VERY IMPORTANT)

This References must be used:

Review Paper:
Derek K. Smitha, b, 1, Miao Hec, d, 1, Chun-Li Zhanga, b, , , Jialin C. Zhengc, e, f, g,
The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders
doi:10.1016/j.pneurobio.2016.01.006

Reference
Kondo et al., 2013
T. Kondo, M. Asai, K. Tsukita, Y. Kutoku, Y. Ohsawa, Y. Sunada, K. Imamura, N. Egawa, N. Yahata, K. Okita, K. Takahashi, I. Asaka, A. Takashi, A. Watanabe, K. Watanabe, C. Kadoya, R. Nakano, D. Watanabe, K. Maruyama, O. Hori, S. Hibino, T. Choshi, T. Nakahata, H. Hioki, T. Kaneko, M. Naitoh, K. Yoshikawa, S. Yamawaki, S. Suzuki, R. Hata, S.-I

. Ueno, T. Seki, K. Kobayashi, T. Toda, K. Murakami, K. Irie, W.L. Klein, H. Mori, T. Asada, R. Takahashi, N. Iwata, S. Yamanaka, H. Inoue
Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular A? and differential drug responsiveness
Cell Stem Cell, 12 (2013), pp. 487–496

Abad et al., 2013
M. Abad, L. Mosteiro, C. Pantoja, M. Cañamero, T. Rayon, I. Ors, O. Graña, D. Megías, O. Domínguez, D. Martínez, M. Manzanares, S. Ortega, M. Serrano
Reprogramming in vivo produces teratomas and iPS cells with totipotency features
Nature, 502 (2013), pp. 340–345

Berninger et al., 2007
B. Berninger, M.R. Costa, U. Koch, T. Schroeder, B. Sutor, B. Grothe, M. Götz
Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia
J. Neurosci., 27 (2007), pp. 8654–8664

M.E. Emborg, Y. Liu, J. Xi, X. Zhang, Y. Yin, J. Lu, V. Joers, C. Swanson, J.E. Holden, S.-C. Zhang
Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain
Cell Rep., 3 (2013), pp. 646–650

Boulting et al., 2011
G.L. Boulting, E. Kiskinis, G. Croft, M.W

. Amoroso, D.H. Oakley, B.J. Wainger, D.J. Williams, D.J. Kahler, M. Yamaki, L. Davidow, C.T. Rodolfa, J.T. Dimos, S. Mikkilineni, A.B. MacDermott, C.J. Woolf, C.E. Henderson, H. Wichterle, K. Eggan
A functionally characterized test set of human induced pluripotent stem cells
Nat. Biotechnol., 29 (2011), pp. 279–28
Dimos et al., 2008
J.T. Dimos, K.T. Rodolfa, K.K. Niakan, L.M. Weisenthal, H. Mitsumoto, W. Chung, G.F. Croft, G. Saphier, R. Leibel, R. Goland, H. Wichterle, C.E. Henderson, K. Eggan
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons
Science, 321 (2008), pp. 1218–1221

P.J. Hallett, M. Deleidi, A. Astradsson, G.A

. Smith, O. Cooper, T.M. Osborn, M. Sundberg, M.A. Moore, E. Perez-Torres, A.-L. Brownell, J.M. Schumacher, R.D. Spealman, O. Isacson
Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease
Cell Stem Cell, 16 (2015), pp. 269–274

Soldner et al., 2011
F. Soldner, J. Laganière, A.W. Cheng, D. Hockemeyer, Q. Gao, R. Alagappan, V. Khurana, L.I. Golbe, R.H

. Myers, S. Lindquist, L. Zhang, D. Guschin, L.K. Fong, B.J. Vu, X. Meng, F.D. Urnov, E.J. Rebar, P.D. Gregory, H.S. Zhang, R. Jaenisch
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations
Cell, 146 (2011), pp. 318–331

Yilmazer et al., 2013
A. Yilmazer, I. de Lázaro, C. Bussy, K. Kostarelos
In vivo cell reprogramming towards pluripotency by virus-free overexpression of defined factors
PLOS ONE, 8 (2013), p. e54754

Warren et al., 2010
L. Warren, P.D. Manos, T. Ahfeldt, Y.-H

. Loh, H. Li, F. Lau, W. Ebina, P.K. Mandal, Z.D. Smith, A. Meissner, G.Q. Daley, A.S. Brack, J.J. Collins, C. Cowan, T.M. Schlaeger, D.J. Rossi
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA
Cell Stem Cell, 7 (2010), pp. 618–630

Why Choose US

6+ years experience on custom writing
80% Return Client
Urgent 2 Hrs Delivery
Your Privacy Guaranteed
Unlimited Free Revisions
Is this question part of your assignment?
Place order
Posted on May 22, 2016Author TutorCategories Question, Questions